Twist Bioscience and IMIDomics Collaborate to Discover Antibodies for Applications in Immune-Mediated Inflammatory Diseases
27 Setembro 2023 - 9:00AM
Business Wire
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling
customers to succeed through its offering of high-quality synthetic
DNA using its silicon platform, and IMIDomics, Inc., a
patient-centric drug discovery and development company focused on
Immune-Mediated Inflammatory Diseases (IMIDs), today announced a
multi-program collaboration whereby Twist will utilize its antigen
development capabilities and Library of Libraries to conduct
antibody discovery activities against targets identified by
IMIDomics.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20230927418930/en/
The targets were identified using IMIDomics’ proprietary
Clinical Discovery Engine™, a multidimensional, integrated, and
data-driven platform for uncovering the underlying mechanisms of
IMIDs. Under the terms of the collaboration, Twist will receive an
upfront and project specific fees and will be eligible to receive
payments associated with specific clinical and commercial
milestones as well as royalty payments on product sales. IMIDomics
will receive human antibodies against several of its priority
targets from Twist.
“This collaboration with IMIDomics brings together expertise in
relevant target identification and antibody discovery, two key
areas needed for successful drug discovery and development,” said
Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience.
“IMIDomics leverages its extensive biobank data to identify targets
not previously associated with IMIDs. To discover antibodies that
are highly specific to these targets, we will leverage the
expertise of our Biopharma Solutions team across sites, utilizing
our Twist Boston team for antigen production, which will be used by
our team in South San Francisco to discover highly specific human
antibody leads for IMIDomics.”
“A significant percentage of patients with IMIDs don’t respond
to existing drugs,” said H. Daniel Perez, M.D., Chief Development
Officer of IMIDomics. “We leverage our proprietary Clinical
Discovery Engine™ to interrogate multiple layers of biological
information to identify targets not previously associated with
immune-mediated inflammatory diseases. We are already at work using
the discoveries we've made to date to develop and validate a robust
pipeline of drug candidates for these diseases. Through our
multi-program collaboration with Twist, we can continue to build on
this work, finding new potential treatments by making this data
actionable and leveraging their extensive capabilities in antibody
discovery to advance our discovery-stage programs.”
About IMIDomics
IMIDomics is a biotechnology company focused on patient-centric
drug discovery for immune-mediated inflammatory diseases (IMIDs).
Our goal is to discover new and impactful IMID drugs by focusing on
carefully selected patients, and stratifying populations to
identify those most likely to respond. IMIDomics is powered by a
unique Clinical Discovery Engine™, which integrates and analyzes
proprietary clinical, epidemiological and patient-derived
biomolecular datasets, generated in partnership with the Vall
d’Hebron Institute of Research, to establish a deeper understanding
of IMID diseases. IMIDomics has identified previously unrecognized
targets, six of which have been selected for development within
IMIDomics’ active drug pipeline. By relying on access to
well-defined patients and their clinically relevant samples,
IMIDomics enhances the probability of successful IMID drug
discovery and development for those in need.
To learn more about IMIDomics, please visit
www.imidomics.com.
About Twist Biopharma Solutions (The Biologics Discovery and
Optimization Division of Twist Bioscience)
Twist Biopharma Solutions combines high-throughput DNA synthesis
technology, deep expertise in antibody engineering and in vivo, in
vitro and in silico discovery methods to provide end-to-end
antibody discovery solutions across the preclinical continuum and
tailored to our partner’s specific needs. By leveraging our unique
ability to manufacture DNA at scale, we can construct proprietary
antibody libraries with discovery beginning with either in vivo or
in vitro diversity. Our Library of Libraries gives our partners an
integral and unbiased resource for antibody therapeutic discovery
and optimization. This precise and rational approach to library
fabrication combined with sophisticated bioinformatics and software
expertise expedites antibody discovery by decreasing risk,
increasing speed, and lowering the failure rate for antibody
therapeutic development. Additionally, in vivo discovery approaches
including single B cell screening and hybridoma discovery enable
parallel paths where multiple technology methods can be leveraged
to create a panel of highly diverse antibody leads. Our automated
screening and panning processes enable us to identify high affinity
leads that our partners can move forward into the clinic. We also
offer supporting development capabilities, including IgG
conversion, expression, purification, biophysical characterization,
and functional characterization.
For more information visit:
https://www.twistbioscience.com/products/antibody-discovery/twist-bioscience-and-abveris
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic
biology and genomics company that has developed a disruptive DNA
synthesis platform to industrialize the engineering of biology. The
core of the platform is a proprietary technology that pioneers a
new method of manufacturing synthetic DNA by “writing” DNA on a
silicon chip. Twist is leveraging its unique technology to
manufacture a broad range of synthetic DNA-based products,
including synthetic genes, tools for next-generation sequencing
(NGS) preparation, and antibody libraries for drug discovery and
development. Twist is also pursuing longer-term opportunities in
digital data storage in DNA and biologics drug discovery. Twist
makes products for use across many industries including healthcare,
industrial chemicals, agriculture and academic research.
Follow us on Twitter | Facebook | LinkedIn | YouTube
Twist Bioscience Legal Notice Regarding Forward-Looking
Statements
This press release contains forward-looking statements. All
statements other than statements of historical facts contained
herein, including, but not limited to, statements regarding the
potential success of the collaboration and the achievement of any
clinical or commercial milestones or product sales, are
forward-looking statements reflecting the current beliefs and
expectations of management made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements involve known and unknown risks,
uncertainties, and other important factors that may cause Twist
Bioscience’s actual results, performance, or achievements to be
materially different from any future results, performance, or
achievements expressed or implied by the forward-looking
statements. Such risks and uncertainties include, among others, the
ability to achieve the expected benefits of Twist Bioscience’s
workforce reduction and reduced investments in DNA data storage;
the ability to attract new customers and retain and grow sales from
existing customers; the ability of Twist to achieve sufficient
revenue to achieve or maintain positive cash flow from operations
or profitability in any given period; risks and uncertainties of
rapidly changing technologies and extensive competition in
synthetic biology that could make the products Twist Bioscience is
developing obsolete or non-competitive; uncertainties of the
retention of significant customers; the ability of Twist Bioscience
to successfully integrate acquired companies and to achieve
expected benefits from acquisitions; supply chain and other
disruptions caused by the COVID-19 pandemic or otherwise; risks of
third party claims alleging infringement of patents and proprietary
rights or seeking to invalidate Twist Bioscience’s patents or
proprietary rights; and the risk that Twist Bioscience’s
proprietary rights may be insufficient to protect its technologies.
For a description of the risks and uncertainties that could cause
actual results to differ from those expressed in these
forward-looking statements, as well as risks relating to Twist
Bioscience’s business in general, see Twist Bioscience’s risk
factors set forth in Twist Bioscience’s Quarterly Report on Form
10-Q filed with the Securities and Exchange Commission on August 7,
2023 and subsequent filings with the SEC. Any forward-looking
statements contained in this press release speak only as of the
date hereof, and Twist Bioscience specifically disclaims any
obligation to update any forward-looking statement, whether as a
result of new information, future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230927418930/en/
For Twist Bioscience: Angela Bitting SVP, Corporate
Affairs 925-202-6211 abitting@twistbioscience.com
For IMIDomics: Shani Lewis Real Chemistry (On behalf of
IMIDomics) slewis@realchemistry.com
Twist Bioscience (NASDAQ:TWST)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Twist Bioscience (NASDAQ:TWST)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024